Physicians Total Care, Inc.
KARIVA — desogestrel/ethinyl estradiol and ethinyl estradiol
Physicians Total Care, Inc.
Rx only
Iss. 12/200911001578
PATIENTS SHOULD BE COUNSELED THAT THIS PRODUCT DOES NOT PROTECT AGAINST HIV INFECTION (AIDS) AND OTHER SEXUALLY TRANSMITTED DISEASES.
DESCRIPTION
Kariva® (desogestrel/ethinyl estradiol and ethinyl estradiol) Tablets provide an oral contraceptive regimen of 21 white round tablets each containing 0.15 mg desogestrel (13-ethyl-11-methylene-18,19-dinor-17 alpha-pregn-4-en- 20-yn-17-ol), 0.02 mg ethinyl estradiol (19-nor-17 alpha-pregna-1,3,5(10)-trien-20-yne-3,17-diol), and inactive ingredients which include colloidal silicon dioxide, hypromellose, lactose monohydrate, polyethylene glycol, povidone, pregelatinized starch, stearic acid and vitamin E, followed by 2 inert light-green round tablets with the following inactive ingredients: FD&C Blue No. 1 Aluminum Lake, FD&C Yellow No. 6 Aluminum Lake, D&C Yellow No. 10 Aluminum Lake, lactose monohydrate, magnesium stearate, microcrystalline cellulose and pregelatinized starch. Kariva® also contains 5 light-blue round tablets containing 0.01 mg ethinyl estradiol (19-nor-17 alpha-pregna-1,3,5 (10)-trien-20-yne-3,17-diol) and inactive ingredients which include colloidal silicon dioxide, FD&C Blue No. 1 Aluminum Lake, FD&C Blue No. 2 Aluminum Lake, hypromellose, lactose monohydrate, polydextrose, polyethylene glycol, povidone, pregelatinized starch, stearic acid, titanium dioxide, triacetin and vitamin E. The molecular weight for desogestrel and ethinyl estradiol are 310.48 and 296.40 respectively. The structural formulas are as follows:
DESOGESTREL M.W. 310.48 MF: C22 H30 O
ETHINYL ESTRADIOL M.W. 296.40 MF: C20 H24 O2
The 21 white tablets meet USP Dissolution Test 2.
CLINICAL PHARMACOLOGY
Combination oral contraceptives act by suppression of gonadotropins. Although the primary mechanism of this action is inhibition of ovulation, other alterations include changes in the cervical mucus (which increase the difficulty of sperm entry into the uterus) and the endometrium (which reduce the likelihood of implantation).
Receptor binding studies, as well as studies in animals, have shown that etonogestrel, the biologically active metabolite of desogestrel, combines high progestational activity with minimal intrinsic androgenicity (91,92). The relevance of this latter finding in humans is unknown.
Pharmaco*kinetics
Absorption
Desogestrel is rapidly and almost completely absorbed and converted into etonogestrel, its biologically active metabolite. Following oral administration, the relative bioavailability of desogestrel compared to a solution, as measured by serum levels of etonogestrel, is approximately 100%. Kariva® (desogestrel/ethinyl estradiol and ethinyl estradiol) Tablets provide two different regimens of ethinyl estradiol; 0.02 mg in the combination tablet [white] as well as 0.01 mg in the light-blue tablet. Ethinyl estradiol is rapidly and almost completely absorbed. After a single dose of Kariva® combination tablet [white], the relative bioavailability of ethinyl estradiol is approximately 93% while the relative bioavailability of the 0.01 mg tablet [light-blue] is 99%. The effect of food on the bioavailability of Kariva® Tablets following oral administration has not been evaluated.
The pharmaco*kinetics of etonogestrel and ethinyl estradiol following multiple dose administration of Kariva® was determined during the third cycle in 17 subjects. Plasma concentrations of etonogestrel and ethinyl estradiol reached steady-state by Day 21. The AUC(0–24) for etonogestrel at steady-state on Day 21 was approximately 2.2 times higher than AUC(0–24) on Day 1 of the third cycle. The pharmaco*kinetic parameters of etonogestrel and ethinyl estradiol during the third cycle following multiple dose administration of Kariva® are summarized in Table I.
Etonorgestrel | ||||||
Day | Dose mg | Cmax | Tmax | t1/2 | AUC0–24 | CL/F |
1 | 0.15 | 2503.6 (987.6) | 2.4 (1.0) | 29.8 (16.3) | 17832 (5674) | 5.4 (2.5) |
21 | 0.15 | 4091.2 (1186.2) | 1.6 (0.7) | 27.8 (7.2) | 39391 (12134) | 4.4 (1.4) |
Cmax — measured peak concentrationTmax — observed time of peak concentrationt1/2 — elimation half-life, calculated by 0.693/Kelim AUC0-24 — area under the concentration-time curve calculated by the linear trapezoidal rule(Time 0 to 24 hours)CL/F — apparent clearance | ||||||
| ||||||
Ethinyl Estradiol | ||||||
Day | Dose | Cmax | Tmax | t1/2 | AUC0–24 | CL/F |
1 | 0.02 | 51.9 (15.4) | 2.9 (1.2) | 16.5 (4.8) | 566 (173)* | 25.7 (9.1) |
21 | 0.02 | 62.2 (25.9) | 2.0 (0.8) | 23.9 (25.5) | 597 (127)* | 35.1 (8.2) |
24 | 0.01 | 24.6 (10.8) | 2.4 (1.0) | 18.8 (10.3) | 246 (65) | 43.6 (12.2) |
28 | 0.01 | 35.3 (27.5) | 2.1 (1.3) | 18.9 (8.3) | 312 (62) | 33.2 (6.6) |
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.
https://medlibrary.org/lib/rx/meds/kariva/